Marta Figueiredo holds a BSc in Biology and a MSc in Evolutionary and Developmental Biology from the University of Lisbon, Portugal. She is currently finishing her PhD in Biomedical Sciences at the University of Lisbon, where she focused her research on the role of several signalling pathways in thymus and parathyroid glands embryonic development.
People with rare disorders have a worse healthcare experience than those affected by chronic diseases, according to the results of an international survey conducted by Eurordis-Rare Diseases Europe. Indeed, rare ... Read more
Switching from conventional therapy to Crysvita (burosumab) leads to clinically relevant reductions in pain and fatigue, and better quality of life, in children with X-linked hypophosphatemia (XLH) ages 5 to 12, ... Read more
A multidisciplinary approach based on pediatrics, orthopedics, and functional therapy specialties is crucial for managing and treating children and adults living with X-linked hypophosphatemia (XLH), experts emphasized on a recent ... Read more
The first wave of COVID-19 in Europe severely disrupted access to care and raised stress and anxiety in people with rare diseases, negatively affecting their health and well-being, according to a ... Read more
Complete clinical and genetic analyses are needed to correctly diagnose X-linked hypophosphatemia (XLH), according to the case study of a woman whose disease was misdiagnosed as osteoporosis for years. The case report, ... Read more
Treatment for nearly two years with Crysvita (burosumab) continued to maintain normal blood levels of phosphate and was found to be safe in adults with X-linked hypophosphatemia (XLH), according to ... Read more
The burden of X-linked hypophosphatemia (XLH) is centered on treatment in childhood, expands to psychological impact and other factors in adolescence, and shifts in adulthood to the need for other ... Read more